Christopher Saddler

Dr. Christopher Saddler


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
MSMichael Scolarici
Michael Scolarici
MJMargaret Jorgenson
Margaret Jorgenson
CSChristopher Saddler
Christopher Saddler
JSJeannina Smith
Jeannina Smith
Invasive fungal infections (IFIs) are one of the most feared complications associated with liver transplantation, with high rates of morbidity and mortality. We discuss the most common invasive fungal infections in the setting of liver transplant, including Candida, Aspergillus, and Cryptococcal infections, and some less frequent but devastating mold infections. Further, we evaluate the use of prophylaxis to prevent invasive fungal infection in this population as a promising mechanism to reduce risks to patients after liver transplant.

27 May 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
MJMargaret R. Jorgenson
Margaret R. Jorgenson
JDJillian L. Descourouez
Jillian L. Descourouez
LSLucas T. Schulz
Lucas T. Schulz
KGKerry A. Goldrosen
Kerry A. Goldrosen
JRJohn P. Rice
John P. Rice
DMDidier Mandelbrot
Didier Mandelbrot
Classical stewardship efforts have targeted immunocompetent patients; however, appropriate use of antimicrobials in the immunocompromised host has become a target of interest. Cytomegalovirus (CMV) infection is one of the most common and significant complications after solid-organ transplant (SOT). The treatment of CMV requires a dual approach of antiviral drug therapy and reduction of immunosuppression for optimal outcomes. This dual approach to CMV management increases complexity and requires individualization of therapy to balance antiviral efficacy with the risk of allograft rejection. In this review, we focus on the development and implementation of CMV stewardship initiatives, as a component of antimicrobial stewardship in the immunocompromised host, to optimize the management of prevention and treatment of CMV in SOT recipients. These initiatives have the potential not only to improve judicious use of antivirals and prevent resistance but also to improve patient and graft survival given the interconnection between CMV infection and allograft function.

20 November 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
MJMargaret R Jorgenson
Margaret R Jorgenson
HKHanna Kleiboeker
Hanna Kleiboeker
NGNeetika Garg
Neetika Garg
SPSandesh Parajuli
Sandesh Parajuli
DMDidier Mandelbrot
Didier Mandelbrot
JSJeannina Smith
Jeannina Smith

26 July 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
MJMargaret R. Jorgenson
Margaret R. Jorgenson
JDJillian L. Descourouez
Jillian L. Descourouez
NGNeetika Garg
Neetika Garg
SPSandesh Parajuli
Sandesh Parajuli
DMDidier Mandelbrot
Didier Mandelbrot
JSJeannina Smith
Jeannina Smith

21 November 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
NGNeetika Garg
Neetika Garg
MJMargaret Jorgenson
Margaret Jorgenson
JDJillian Descourouez
Jillian Descourouez
CSChristopher Saddler
Christopher Saddler
SPSandesh Parajuli
Sandesh Parajuli
DMDidier Mandelbrot
Didier Mandelbrot
The goal of this study was to identify predictors for development of Pneumocystis jirovecii pneumonia (PJP) in kidney and simultaneous kidney and pancreas transplant recipients in the present era of universal primary prophylaxis. We reviewed adult recipients of kidney transplant or simultaneous pancreas and kidney transplant at the University of Wisconsin between January 1, 1994 and December 31, 2016. Patients diagnosed with PJP during this time frame were included. Controls were randomly selected from among those whose post-transplant course was not complicated by PJP, matched on time since transplant through incidence density sampling with a 3:1 ratio. 28 (0.45%) of 6270 recipients developed PJP between 1994 and 2016. Median time since transplant was 4.6 years (interquartile range (IQR): 1.4–9.6 years). Affected recipients were older, had more HLA mismatches, and were more likely to have had BK viremia, CMV viremia and invasive fungal infections than matched controls. CMV viremia remained the only significant risk factor in multivariate analysis, and was a strong predictor (OR 6.27; p = 0.002). Ninety percent of the cases with prior CMV viremia had been diagnosed in the year preceding the diagnosis of PJP; among these, median time from diagnosis of CMV to diagnosis of PJP was 3.4 months (IQR: 1.74–11.5 months) and median peak CMV viral load prior to diagnosis of PJP was 3684.5 IU/mL (IQR: 1034–93,300 IU/mL). Additionally, 88.9% of patients with CMV in the preceding year had active infection at time of PJP diagnosis. Patient and graft survival were significantly worse at 2 years in recipients with PJP than our control group (42.4% vs. 88.5, and 37.9% vs. 79.9%; p < 0.001). Despite the low overall incidence of PJP in the era of universal prophylaxis, outcomes are poor. We suggest extending or re-initiating PJP prophylaxis for at least 6 months in the setting of CMV viremia due to the relatively low risk of therapy and potential significant impact on disease prevention.

9 May 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
FAFahad Aziz
Fahad Aziz
CSChristopher Saddler
Christopher Saddler
MJMargaret Jorgenson
Margaret Jorgenson
JSJeannina Smith
Jeannina Smith
DMDidier Mandelbrot
Didier Mandelbrot